Theophylline: biochemical pharmacology and pharmacokinetics.
Theophylline and its derivatives, such as aminophylline, have an established role as bronchodilators, although their mode of action in man is not clear. There is circumstantial evidence that therapeutic doses of theophylline may have a phosphodiesterase inhibiting effect, thus potentiating the effects of cyclic AMP. However, it remains to be established whether this is the primary mode of action of theophylline at the biochemical level. The pathways of theophylline metabolism have been clarified, although most of the enzymes involved have not been characterized. Hepatic microsomal enzyme induction by polycyclic hydrocarbons will increase the rate of theophylline elimination. There are a number of factors which influence theophylline clearance in adults, which is known to be highly variable. These factors include obesity, smoking habit, diet and the presence of such diseases as hepatic cirrhosis, acute pulmonary oedema, cor pulmonale and viral respiratory infection. There is a good correlation between plasma theophylline level and bronchodilator effect. This can be demonstrated at plasma levels as low as 5 microgram/ml, although optimal levels are usually greater than 10 microgram/ml. Unacceptable toxicity usually occurs in association with plasma levels greater than 20 microgram/ml. The maintenance of adequate plasma theophylline levels by the use of a sustained-release aminophylline tablet is discussed.
D000628:Aminophylline / Q000008:administration & dosage / Q000378:metabolism; D000242:Cyclic AMP / Q000097:blood / Q000378:metabolism; D003692:Delayed-Action Preparations; D006801:Humans; D007700:Kinetics; D013806:Theophylline / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*
D003692:Delayed-Action Preparations; D000628:Aminophylline; D013806:Theophylline; D000242:Cyclic AMP